A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 330-339

  Gorse, Geoffrey J ^a   Keefer, Michael C ^b   Belshe, Robert B ^b   Matthews, Thomas J ^b   Forrest, Bruce D ^b   Hsieh, Ray Hahn ^b   Koff, Wayne C ^b   Hanson, Carl V ^b   Dolin, Raphael ^b   Weinhold, Kent J ^b   Frey, Sharon E ^b   Ketter, Nzeera ^b   Fast, Patricia E ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS;

EID: 9044226537     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.330     Document Type: Article

References (15)

1. Dolin R, Graham BS, Greenberg SB, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-27.
2. Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in low-risk volunteers. J Infect Dis 1993;168:1387-95.
3. Gorse GJ, Schwartz DH, Graham BS, et al. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol 1994;98:178-84.
4. B rgp120 subunit vaccine. Lancet 1993;342:69-73.
5. SF2 rgp120 candidate vaccine [abstract PO-A29-0692]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993:250.
6. McElrath MJ, Corey L, Clements ML, et al. A phase II HIV prophylactic vaccine trial in seronegative volunteers: expanded safety and immunogenicity evaluation of two recombinant gp120 vaccines [abstract 1241]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994:238.
7. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-80.
8. Keefer MC, Graham BS, Belshe RB, et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses 1994;10:1713-23.
9. Kovacs JA, Vasudevachari MB, Easter M, et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV seronegative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28.
10. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994;170:1288-91.
11. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-6.
12. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992;166:244-52.
13. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-7.
14. Excler JL, Salmon D, Pialoux G, Plotkin S, AGIS Group. A prime-boost approach to human immunodeficiency virus preventive vaccines using recombinant canarypox virus and envelope subunits [abstract 1134]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993:327.
15. Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-5.